(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pick Your #1 Kind Of Treat - 2Surging measles cases are 'fire alarm' warning that other diseases could be next
- 3Figure out how to Team up with Your Auto Crash Legal advisor for Best Outcomes
- 48 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- 5Family Matters: Tips and Guidance for Effective Nurturing and Everyday Life
- 6 Well known Nissan Vehicles in the U.S.
- Vote In favor of Your Favored Sort Of Bevarage
- 25 Most Beautiful Villages in France You Can Actually Visit
- The Way to Fruitful Weight reduction: Individual Wellbeing Excursions
- From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- When preventable infections turn deadly behind bars | The Excerpt
- Vote in favor of your #1 sort of juice
- Step by step instructions to Buy a Jeep Wrangler on a Senior's Spending plan
- SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
